18 May 2017
On May 8, 2017, the European Medicines Agency (EMA) released a report on its pilot project to involve patients in the benefit-risk assessment of medicines at Committee for Medicinal Products for Human Use (CHMP) meetings. The agency concluded that patient involvement was beneficial and should continue.
The pilot project, which ran from September 2014 to December 2016, involved patients participating in discussions at the CHMP. Six medicines were evaluated in the pilot project. Patient input was considered when CHMP was evaluating authorization for new drugs; the maintenance, suspension, or revocation of an existing authorized drug; or restrictions on indications of authorized drugs.
Due to the positive outcome of the pilot project, CHMP decided to develop additional ways patients can be involved in CHMP discussions, such as teleconferences or organized written consultations. Patients also assist EMA in other ways, including as members of the various agency committees, as experts in scientific advice procedures and advisory groups, in reviewing information documents, and as members of the Patients’ and Consumers Working Party.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024